Search research articles
Contact Us
Filters
Showing results (251-260 of 353) with videos related to
Page
of 36
Sort By:
Clinical Pharmacokinetics
|
August 21, 2020
Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer
Neeraj Gupta, Xiaohui Wang, Elliot Offman, et al.
Clinical Pharmacology in Drug Development
|
July 10, 2019
Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
Meera Tugnait, Neeraj Gupta, Michael J Hanley, et al.
Journal of Clinical Pharmacology
|
February 14, 2016
The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma
Neeraj Gupta, Michael J Hanley, Karthik Venkatakrishnan, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
September 17, 2024
Modeling serum M-protein response for early detection of biochemical relapse in myeloma patients treated with bortezomib, lenalidomide and dexamethasone
Yuki Otani, Yunqi Zhao, Guanyu Wang, et al.
Indian Journal of Critical Care Medicine : Peer-Reviewed, Official Publication of Indian Society of Critical Care Medicine
|
July 28, 2021
Tracheostomy in Pediatric Intensive Care Unit-A Two Decades of Experience
Anil Sachdev, Nilay D Chaudhari, Bhanu P Singh, et al.
Clinical Pharmacology in Drug Development
|
December 21, 2018
The Effect of a High-Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
Meera Tugnait, Neeraj Gupta, Michael J Hanley, et al.
Diabetes Technology & Therapeutics
|
December 17, 2009
Ileal interposition with sleeve gastrectomy for control of type 2 diabetes
K V S Hari Kumar, Surendra Ugale, Neeraj Gupta, et al.
Clinical Pharmacology in Drug Development
|
June 12, 2021
Single-Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK-788) in Healthy Volunteers: Low-Fat Meal Effect and Relative Bioavailability of 2 Capsule Products
Steven Zhang, Shu Jin, Celina Griffin, et al.
Clinical Pharmacology and Therapeutics
|
April 25, 2022
Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure-Response Analyses of a Pivotal Phase I/II Study
Neeraj Gupta, Anna Largajolli, Han Witjes, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
January 30, 2024
Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach
Michael J Hanley, Karen Rowland Yeo, Meera Tugnait, et al.
Page
of 36
Search research articles
Search
Showing results (251-260 of 353) with videos related to
Sort By:
Page
of 36
Clinical Pharmacokinetics
|
August 21, 2020
Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer
Neeraj Gupta, Xiaohui Wang, Elliot Offman, et al.
Clinical Pharmacology in Drug Development
|
July 10, 2019
Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
Meera Tugnait, Neeraj Gupta, Michael J Hanley, et al.
Journal of Clinical Pharmacology
|
February 14, 2016
The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma
Neeraj Gupta, Michael J Hanley, Karthik Venkatakrishnan, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
September 17, 2024
Modeling serum M-protein response for early detection of biochemical relapse in myeloma patients treated with bortezomib, lenalidomide and dexamethasone
Yuki Otani, Yunqi Zhao, Guanyu Wang, et al.
Indian Journal of Critical Care Medicine : Peer-Reviewed, Official Publication of Indian Society of Critical Care Medicine
|
July 28, 2021
Tracheostomy in Pediatric Intensive Care Unit-A Two Decades of Experience
Anil Sachdev, Nilay D Chaudhari, Bhanu P Singh, et al.
Clinical Pharmacology in Drug Development
|
December 21, 2018
The Effect of a High-Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
Meera Tugnait, Neeraj Gupta, Michael J Hanley, et al.
Diabetes Technology & Therapeutics
|
December 17, 2009
Ileal interposition with sleeve gastrectomy for control of type 2 diabetes
K V S Hari Kumar, Surendra Ugale, Neeraj Gupta, et al.
Clinical Pharmacology in Drug Development
|
June 12, 2021
Single-Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK-788) in Healthy Volunteers: Low-Fat Meal Effect and Relative Bioavailability of 2 Capsule Products
Steven Zhang, Shu Jin, Celina Griffin, et al.
Clinical Pharmacology and Therapeutics
|
April 25, 2022
Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure-Response Analyses of a Pivotal Phase I/II Study
Neeraj Gupta, Anna Largajolli, Han Witjes, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
January 30, 2024
Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach
Michael J Hanley, Karen Rowland Yeo, Meera Tugnait, et al.
Page
of 36